Previously, we have proposed two strategies to ascertain the utility of EMT reversal in carcinoma: the first, assessing EMT-related functions, such as the induction of colony compaction; the second, inducing re-differentiation of mesenchymal-like cells by the upregulation of epithelial markers, such as E-cadherin.9 In this study, we utilized the second approach and established a 3-phase drug discovery pipeline and identified HDACi to be a potent class of compounds to restore epithelial differentiation. This evidence concerns the gene CDH1 and carcinoma.